Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Amortization - Goodwill Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Shares Issued Shares Outstanding Shares Outstanding Shares Repurchased

Anika Therapeutics (ANIK) Shares Issued (2016 - 2024)

Anika Therapeutics has reported Shares Issued over the past 15 years, most recently at -$335000.0 for Q4 2024.

Quarterly Shares Issued fell 2292.86% to -$335000.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$335000.0 through Sep 2025, down 184.38% year-over-year, with the annual reading at $76000.0 for FY2024, 230.43% up from the prior year.
Shares Issued was -$335000.0 for Q4 2024 at Anika Therapeutics, down from $388000.0 in the prior quarter.
Over five years, Shares Issued peaked at $650000.0 in Q4 2022 and troughed at -$335000.0 in Q4 2024.
The 5-year median for Shares Issued is $26500.0 (2023), against an average of $152000.0.
The largest YoY upside for Shares Issued was 1193.33% in 2024 against a maximum downside of 2292.86% in 2024.
A 5-year view of Shares Issued shows it stood at -$68000.0 in 2020, then surged by 267.65% to $114000.0 in 2021, then soared by 470.18% to $650000.0 in 2022, then plummeted by 102.15% to -$14000.0 in 2023, then plummeted by 2292.86% to -$335000.0 in 2024.
Per Business Quant, the three most recent readings for ANIK's Shares Issued are -$335000.0 (Q4 2024), $388000.0 (Q2 2024), and $23000.0 (Q1 2024).